Healthcare entity
Negative sentiment reaches 0% here, compared with 26% across the 859-story beat baseline for the same window. Each story carries 2 original sources on average, compared with 3.5 for the broader beat in this window. The 177-day window averages about 0.2 stories each week.
Last mentioned: 11h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Negative sentiment reaches 0% here, compared with 26% across the 859-story beat baseline for the same window. Each story carries 2 original sources on average, compared with 3.5 for the broader beat in this window. The 177-day window averages about 0.2 stories each week. At 5.3, the average consequence score sits below the same-window beat average of 6. Of the tracked stories, 1 of 6 also mention Briefing.com, the most common co-covered peer. Coverage clusters in market-trends, which accounts for 2 of those 6, with the remainder spread across 4 other categories. We currently track 6 Healthcare stories that mention Nasdaq, published between March 13, 2026 and September 5, 2026.
Computed from the 6 stories linked to this entity, with beat comparisons drawn from all 859 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nasdaq. Shared-story counts are live from our verified record — not editorial picks.
Valion Bio announces technical assessment underway
Valion Bio issued a press release stating the Ministry has begun technical assessment and issued a first round of questions on physicochemical characterization.
Ukraine MOH accepts Entolimod dossier
Ukraine's Ministry of Health accepted Valion Bio's regulatory dossier for Entolimod for formal review under the Regulatory Equivalence Pathway.
Financial Reporting
Lifeward scheduled to report Q4 and full-year 2025 financial results.
Shareholder Approval
Lifeward shareholders vote in favor of the strategic partnership with Oramed.
Nasdaq Compliance
Lifeward regains compliance with Nasdaq minimum bid price requirements.
bioAffinity's CyPath Lung test volume grew 216% year over year, and the company is now expanding into post-treatment surveillance for lung-cancer patients. The move could widen the test's clinical role beyond initial diagnostic decisions.
Ukraine's Ministry of Health has moved Valion Bio's Entolimod dossier into technical assessment, a step toward what would be the drug's first national registration as an acute radiation syndrome countermeasure. The company says a decision could come as early as Q4 2026, though no procurement or stockpiling agreement exists.
Source: hawaiitelegraph.com · finanznachrichten.de
SNDL’s completion of the Parallel asset acquisition gives it indirect control of medical cannabis operations in three states, positioning the company to directly expand patient access and standardize products once Nasdaq consolidation is achieved.
Source: stockhouse.com · thestarphoenix.com
Heartflow (NASDAQ: HTFL) reported a significant 40.5% year-over-year revenue increase in its latest quarterly results, though earnings per share fell short of analyst expectations. The company posted a loss of $0.29 per share, missing the consensus estimate of $0.16 as it continues to invest heavily in market expansion.
Source: Zolmax · Daily Political
Hologic, Inc. (NASDAQ: HOLX) has experienced a dramatic 71.7% increase in short interest, signaling a significant shift in investor sentiment toward the medical technology leader. This surge suggests growing skepticism regarding the company's near-term growth prospects in its core women's health and diagnostics segments.
Source: tickerreport.com · dailypolitical.com
Lifeward Ltd shareholders have officially approved a strategic partnership with Oramed Pharmaceuticals, signaling a major pivot toward becoming a diversified biomedical company. The deal integrates Lifeward's robotic rehabilitation technology with Oramed's pharmaceutical expertise to create a multi-disciplinary healthcare entity.
Source: finanznachrichten.de · manilatimes.net
Nasdaq is linked from 6 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
